Serum programmed death ligand 2 is elevated in cats with mammary carcinoma | Scientific Reports

Nature·Feb 24

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research has found that serum programmed death ligand 2 is elevated in cats with mammary carcinoma. Other studies are exploring various biomarkers and immune responses in different diseases, including vasculitis, pregnancy loss, and various types of cancer. The relevance of these findings to feline mammary carcinoma is being investigated, with some studies examining the role of specific antibodies and proteins.

Full coverage

Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy

Frontiers·Feb 4

Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies

The Lancet·May 18

Elevated expression of immune checkpoints and pro-inflammatory cytokines as potential biomarkers in pediatric Vulvar Lichen Sclerosus | Scientific Reports

Nature·Feb 2

Clinical Relevance of the serum CTLA-4 in Cats with Mammary Carcinoma

Nature·Mar 2

The implication of autoantibodies in early diagnosis and monitoring of plasmonic photothermal therapy in the treatment of feline mammary carcinoma | Scientific Reports

Nature·May 17

Development of anti-feline PD-1 antibody and its functional analysis

Nature·Apr 24

Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma

Nature·Feb 26

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

Nature·Feb 19

View original report at Nature ↗

Fetching the latest headlines…